Biosimilar Drugs for RA Studied in Multiple Trials

Estándar

The Rheumatologist

August 17, 2015 • By

Etanercept Biosimilars

A number of Phase 3 trials are ongoing for etanercept biosimilars.1One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection site reactions and immunogenicity. The RA trials are evaluating ACR20 as the primary endpoint. Secondary endpoints include ACR50, ACR70, DAS28, AEs, serious AEs, safety and immunogenicity.

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión /  Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión /  Cambiar )

Conectando a %s